文献速递临床试验与 GCP

氧化镁与纳地美定预防阿片类药物所致便秘比较:MAGNET概念验证随机对照试验

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
PubMed 文献 · Trials · 2020-06-01

本研究为在日本开展的概念验证、前瞻性、开放标签、II期随机对照试验,计划纳入同时开始阿片类治疗和便秘预防治疗的成人癌症患者,随机分配至氧化镁组(500 mg 每日三次)或纳地美定组(0.2 mg 每日一次),口服12周。主要终点为治疗2周时日本版患者便秘生活质量评估问卷(JPAC-QOL)评分较基线的改善。

要点

  • 比较氧化镁与纳地美定预防阿片类药物所致便秘的疗效。
  • 主要终点为2周时JPAC-QOL评分较基线变化。
  • 关键次要终点为2周和12周时自发性排便变化。

核心结论

  • 本研究旨在确定氧化镁与纳地美定哪个对预防阿片类药物所致便秘更有效。

研究设计与样本

  • 概念验证、前瞻性、随机对照、开放标签、II期试验,在日本的单中心开展,于2018年3月启动。
  • 计划纳入同时开始阿片类治疗和便秘预防治疗的成人癌症患者,随机分配至氧化镁组(500 mg 每日三次)或纳地美定组(0.2 mg 每日一次),口服12周。

关键数值与推荐

  • 主要终点为治疗2周时日本版患者便秘生活质量评估问卷(JPAC-QOL)评分较基线的改善。
  • 关键次要终点为治疗2周和12周时自发性排便的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients taking opioids are known to develop opioid-induced constipation (OIC), which reduces their quality of life. The aim of this study is to compare magnesium oxide with naldemedine and determine which is more effective in preventing OIC. METHODS: This proof-of-concept, prospective, randomized controlled trial commenced in Japan in March 2018. Initially, a questionnaire-based survey will be conducted targeting adult patients with cancer who concomitantly commenced opioid treatment and OIC prevention treatment. Patients will then be randomly allocated to a magnesium oxide group (500 mg thrice daily) or a naldemedine group (0.2 mg once daily). Each drug will be orally administered for 12 weeks. The primary endpoint is defined as any improvement in scores on the Japanese version of Patient Assessment of Constipation Quality of Life questionnaire (JPAC-QOL) from baseline to 2 weeks of treatment. DISCUSSION: The primary endpoint is change in JPAC-QOL score from baseline to 2 weeks of intervention. The key secondary endpoint will be change in spontaneous bowel movements at 2 and 12 weeks of intervention. This study will determine whether magnesium oxide or naldemedine is more effective for the prevention of OIC. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) Clinical Trials Registry, UMIN000031891. Registered March 25, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ozaki A, Kessoku T, Iwaki M, et al. Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. Trials. 2020. PMID: 32487150. doi:10.1186/s13063-020-04385-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。